1. Phylogeny  
MOK, also known as MAPK/MAK/MRK overlapping kinase or Renal tumor antigen 1, is a serine/threonine protein kinase classified within the RCK kinase family, whose members include MAK (male germ cell-associated kinase) and ICK (intestinal cell kinase) (miyata2001specificassociationof pages 1-1). It is phylogenetically positioned within the CMGC group of kinases, which encompasses classic mitogen‐activated protein kinases (MAPKs) as well as cyclin‐dependent kinases (CDKs), thereby reflecting an evolutionary relationship that bridges these two major kinase families (pearson2001mitogenactivatedprotein(map) pages 6-8). Orthologs of MOK have been identified in a broad range of species, indicating that the core regulatory and signaling functions mediated by this kinase are conserved from unicellular organisms to mammals (howard2014ancestralresurrectionreveals pages 11-13, canning2018cdklfamilykinases pages 1-3).

2. Reaction Catalyzed  
MOK catalyzes the transfer of a phosphate group from ATP to specific serine/threonine residues on protein substrates. In its catalysis, the general chemical conversion follows the reaction: ATP + [protein]-(L‑serine or L‑threonine) → ADP + [protein]-(L‑serine/threonine)-phosphate + H⁺ (miyata2001specificassociationof pages 1-1, garske2011chemicalgeneticstrategy pages 3-4).

3. Cofactor Requirements  
The catalytic activity of MOK, like that of most serine/threonine protein kinases, requires the presence of divalent metal ions, with Mg²⁺ being essential for correctly positioning ATP within the active site to facilitate the phosphate-transfer reaction (kim2005proteinkinaseb pages 39-45).

4. Substrate Specificity  
MOK has been shown to phosphorylate several exogenous substrates as well as undergo autophosphorylation; however, a specific consensus substrate motif has not been definitively characterized in the available literature. On the basis of its close relationship to other RCK family kinases, it is anticipated that MOK preferentially modifies serine/threonine residues within target proteins that may present basic residues in the vicinity of the phosphoacceptor site, yet this remains to be explicitly delineated in high‐throughput substrate specificity studies (miyata2001specificassociationof pages 1-1, chowdhury2023cmgckinasesin pages 12-13).

5. Structure  
The primary structure of MOK is organized into a highly conserved N‑terminal serine/threonine kinase domain and a variable, nonconserved C‑terminal region that currently lacks defined functional motifs. The kinase domain contains the canonical 12 subdomains characteristic of the protein kinase superfamily, including a critical ATP‑binding pocket with a conserved lysine residue, and an activation loop bearing the TXY motif that is essential for catalytic regulation (miyata2001specificassociationof pages 5-6, pearson2001mitogenactivatedprotein(map) pages 6-8). Based on structural models of homologous kinases, the three‑dimensional organization of MOK is anticipated to feature a bilobed structure consisting of an N‑terminal lobe (primarily β‑sheet) and a C‑terminal lobe (largely α‑helical). Notably, the N‑terminal domain is also responsible for the specific interaction with the molecular chaperone HSP90, which is crucial for protecting the proper folding and stability of MOK (miyata2001specificassociationof pages 5-6, 6-7, canning2018cdklfamilykinases pages 1-3).

6. Regulation  
MOK is regulated through post‑translational modifications and protein–protein interactions. It undergoes autophosphorylation, a reaction indicative of its intrinsic catalytic activity, and it is also capable of phosphorylating exogenous substrates in vitro (miyata2001specificassociationof pages 1-1). In addition, MOK phosphorylates the molecular chaperone Cdc37—a component of the HSP90 chaperone machinery—while HSP90 itself is not significantly phosphorylated by MOK; this selective modification has been demonstrated by in vitro kinase assays (miyata2001specificassociationof pages 6-6, 6-7). Unlike conventional MAP kinases, MOK is not robustly activated by classical MAPK stimuli such as serum or osmotic shock, but its activity is elevated in response to tumor promoter treatment, exemplified by 12‑O‑tetradecanoylphorbol‑13‑acetate (TPA), in a phosphorylation‑dependent manner (miyata2001specificassociationof pages 1-1). Furthermore, MOK possesses an endogenous cysteine gatekeeper residue that distinguishes it from many other kinases and provides a chemical genetic handle for the development of covalent inhibitors (garske2011chemicalgeneticstrategy pages 3-4).

7. Function  
Functionally, MOK phosphorylates multiple exogenous substrates and is capable of autophosphorylation, activities that underscore its role in intracellular signal transduction (miyata2001specificassociationof pages 1-1). It negatively regulates primary cilium length, and this function is coupled to cAMP and mTORC1 signaling pathways, suggesting a role in the modulation of ciliogenesis and related cellular transport mechanisms. Expression data indicate that MOK is associated with tissues such as testis, in line with its alternative designation as a renal tumor antigen, and it may play a role in cellular processes related to proliferation and differentiated cellular signaling (miyata2001specificassociationof pages 1-1, chowdhury2023cmgckinasesin pages 12-13, howard2014ancestralresurrectionreveals pages 11-13).

8. Other Comments  
MOK is also known by the alternative name Renal tumor antigen 1, a designation that reflects its initial identification in the context of tumor biology. Its unique structural feature—an endogenous cysteine gatekeeper residue—renders MOK an attractive target for covalent chemical genetic strategies and potentially for the design of selective inhibitors (garske2011chemicalgeneticstrategy pages 3-4). To date, no clinically approved inhibitors that selectively target MOK have been reported, and the precise consensus substrate motif for MOK remains to be comprehensively defined in substrate specificity studies (miyata2001specificassociationof pages 1-1, chowdhury2023cmgckinasesin pages 12-13).

9. References  
1. Miyata, Y., Ikawa, Y., Shibuya, M., & Nishida, E. Specific association of a set of molecular chaperones including HSP90 and Cdc37 with MOK, a member of the mitogen-activated protein kinase superfamily. The Journal of Biological Chemistry, 276:21841-21848, Jun 2001 (miyata2001specificassociationof pages 1-1, 1-2, 5-6, 6-6, 6-7, 7-8).  
2. Chowdhury, I., Dashi, G., & Keskitalo, S. CMGC kinases in health and cancer. Cancers, Jul 2023, pages 12-13 (chowdhury2023cmgckinasesin pages 12-13).  
3. Howard, C.J., Hanson-Smith, V., Kennedy, K.J., Miller, C.J., Lou, H.J., Johnson, A.D., Turk, B.E., & Holt, L.J. Ancestral resurrection reveals evolutionary mechanisms of kinase plasticity. eLife, Oct 2014, pages 11-13 (howard2014ancestralresurrectionreveals pages 11-13).  
4. Canning, P., Park, K., Gonçalves, J., Li, C., Howard, C.J., Sharpe, T.D., Holt, L.J., Pelletier, L., Bullock, A.N., & Leroux, M.R. CDKL family kinases have evolved distinct structural features and ciliary function. Cell Reports, 22:885-894, Jan 2018, pages 1-3 (canning2018cdklfamilykinases pages 1-3).  
5. Garske, A.L., Peters, U., Cortesi, A.T., Perez, J.L., & Shokat, K.M. Chemical genetic strategy for targeting protein kinases based on covalent complementarity. Proceedings of the National Academy of Sciences, 108:15046-15052, Aug 2011, pages 3-4 (garske2011chemicalgeneticstrategy pages 3-4).  
6. Pearson, G., Robinson, F.L., Gibson, T., Xu, B.-E., Karandikar, M., Berman, K., & Cobb, M. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocrine Reviews, 22:153-183, Apr 2001, pages 6-8 (pearson2001mitogenactivatedprotein(map) pages 6-8).  
7. Kim, K.-T., Mok, M.T.S., & Edwards, M.R. Protein kinase B from Giardia intestinalis. Biochemical and Biophysical Research Communications, 334:333-341, Aug 2005, pages 39-45 (kim2005proteinkinaseb pages 39-45).

References

1. (chowdhury2023cmgckinasesin pages 12-13): Iftekhar Chowdhury, Giovanna Dashi, and S. Keskitalo. Cmgc kinases in health and cancer. Cancers, Jul 2023. URL: https://doi.org/10.3390/cancers15153838, doi:10.3390/cancers15153838. This article has 19 citations and is from a peer-reviewed journal.

2. (howard2014ancestralresurrectionreveals pages 11-13): Conor J Howard, Victor Hanson-Smith, Kristopher J Kennedy, Chad J Miller, Hua Jane Lou, Alexander D Johnson, Benjamin E Turk, and Liam J Holt. Ancestral resurrection reveals evolutionary mechanisms of kinase plasticity. eLife, Oct 2014. URL: https://doi.org/10.7554/elife.04126, doi:10.7554/elife.04126. This article has 66 citations and is from a domain leading peer-reviewed journal.

3. (miyata2001specificassociationof pages 1-1): Y. Miyata, Y. Ikawa, M. Shibuya, and E. Nishida. Specific association of a set of molecular chaperones including hsp90 and cdc37 with mok, a member of the mitogen-activated protein kinase superfamily*. The Journal of Biological Chemistry, 276:21841-21848, Jun 2001. URL: https://doi.org/10.1074/jbc.m010944200, doi:10.1074/jbc.m010944200. This article has 92 citations.

4. (miyata2001specificassociationof pages 5-6): Y. Miyata, Y. Ikawa, M. Shibuya, and E. Nishida. Specific association of a set of molecular chaperones including hsp90 and cdc37 with mok, a member of the mitogen-activated protein kinase superfamily*. The Journal of Biological Chemistry, 276:21841-21848, Jun 2001. URL: https://doi.org/10.1074/jbc.m010944200, doi:10.1074/jbc.m010944200. This article has 92 citations.

5. (miyata2001specificassociationof pages 6-6): Y. Miyata, Y. Ikawa, M. Shibuya, and E. Nishida. Specific association of a set of molecular chaperones including hsp90 and cdc37 with mok, a member of the mitogen-activated protein kinase superfamily*. The Journal of Biological Chemistry, 276:21841-21848, Jun 2001. URL: https://doi.org/10.1074/jbc.m010944200, doi:10.1074/jbc.m010944200. This article has 92 citations.

6. (pearson2001mitogenactivatedprotein(map) pages 6-8): G. Pearson, Fred L Robinson, T. Gibson, Bing-e Xu, M. Karandikar, K. Berman, and M. Cobb. Mitogen-activated protein (map) kinase pathways: regulation and physiological functions. Endocrine Reviews, 22:153-183, Apr 2001. URL: https://doi.org/10.1210/er.22.2.153, doi:10.1210/er.22.2.153. This article has 5942 citations and is from a domain leading peer-reviewed journal.

7. (canning2018cdklfamilykinases pages 1-3): Peter Canning, Kwangjin Park, João Gonçalves, Chunmei Li, Conor J. Howard, Timothy D. Sharpe, Liam J. Holt, Laurence Pelletier, Alex N. Bullock, and Michel R. Leroux. Cdkl family kinases have evolved distinct structural features and ciliary function. Cell Reports, 22:885-894, Jan 2018. URL: https://doi.org/10.1016/j.celrep.2017.12.083, doi:10.1016/j.celrep.2017.12.083. This article has 80 citations and is from a highest quality peer-reviewed journal.

8. (garske2011chemicalgeneticstrategy pages 3-4): Adam L. Garske, Ulf Peters, Arianna T. Cortesi, Jenny L. Perez, and Kevan M. Shokat. Chemical genetic strategy for targeting protein kinases based on covalent complementarity. Proceedings of the National Academy of Sciences, 108:15046-15052, Aug 2011. URL: https://doi.org/10.1073/pnas.1111239108, doi:10.1073/pnas.1111239108. This article has 120 citations.

9. (kim2005proteinkinaseb pages 39-45): Kyu-Tae Kim, Myth T.S. Mok, and Michael R. Edwards. Protein kinase b from giardia intestinalis. Biochemical and Biophysical Research Communications, 334:333-341, Aug 2005. URL: https://doi.org/10.1016/j.bbrc.2005.06.106, doi:10.1016/j.bbrc.2005.06.106. This article has 32 citations and is from a peer-reviewed journal.